Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FT576 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Regimens A-A4 | EXPERIMENTAL | FT576 single dose monotherapy in subjects with r/r MM |
| Regimen A1 | EXPERIMENTAL | FT576 multiple dose monotherapy in subjects with r/r MM |
| Regimens B-B4 | EXPERIMENTAL | FT576 single dose in combination with daratumumab in subjects with r/r MM |
| Regimen B1 | EXPERIMENTAL | FT576 multiple dose in combination with daratumumab in subjects with r/r MM |
| Name | Type | Description |
|---|---|---|
| FT576 (Allogenic CAR NK cells with BCMA expression) | DRUG | Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF). |
| Cyclophosphamide | DRUG | Conditioning Agent |
| Fludarabine | DRUG | Conditioning Agent |
| Daratumumab | DRUG | Anti-CD38 Monoclonal Antibody |
| Bendamustine | DRUG | Conditioning Agent |
* Abbreviated inclusion criteria: Diagnosis of r/r MM with measurable disease by at least one of the following: * Serum M-protein ≥1.0 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain level ≥10 mg/dL, with an abnormal kappa-lambda ratio if the serum M-protein \<1.0 g/dL an...
Top 20 of 25 competitors
FT576 is an investigational cell therapy being studied for the treatment of multiple myeloma. It is designed for patients with this blood cancer and was evaluated in a Phase 1 clinical trial. It is not approved for commercial use and remains in clinical development.
FT576 targets BCMA, a protein expressed on multiple myeloma cells. BCMA is a validated target in myeloma therapy. FT576 is an allogeneic CAR NK cell therapy engineered with BCMA expression, meaning it uses donor-derived natural killer cells modified to recognize BCMA.
FT576 is being developed by Fate Therapeutics, Inc., a biopharmaceutical company focused on cell therapies. The company trades on the Nasdaq under the ticker FATE. Fate Therapeutics is responsible for the clinical development of FT576.
FT576 is in Phase 1 clinical development. It has completed one Phase 1 trial in multiple myeloma. It is investigational and has not been approved by the FDA for any indication.
FT576 has been studied in one completed Phase 1 clinical trial, NCT05182073, titled FT576 in Subjects With Multiple Myeloma. The trial enrolled 31 participants in the United States and included adult patients with multiple myeloma. No active trials are currently listed.